The U.S. Food and Drug Administration (FDA) has officially approved Zanvastro, marking the first-ever drug designed to directly target Alexander disease, a devastating and often fatal neurological disorder. Developed through three decades of rigorous research at the University of Wisconsin-Madison, clinical trials demonstrated that the breakthrough treatment successfully stabilizes motor functions and significantly improves physical movement in affected patients. This landmark approval offers new therapeutic hope for families affected by this progressive nervous system illness.
About the Author
